C1orf14_1700012A16Rik Inhibitors
C1orf14_1700012A16Rik inhibitors are a class of chemical compounds that engage in the selective attenuation of this protein's activity through various mechanisms. These inhibitors include molecules like Rapamycin and its derivatives, such as Everolimus and Temsirolimus, which bind to FKBP-12, leading to a targeted inhibition of mTORC1. This specific inhibition is critical because C1orf14_1700012A16Rik is implicated in the downstream effects of mTORC1 signaling, which governs cell growth and proliferation. The dampening of this pathway by these inhibitors results in a subsequent decrease in the functional activity of C1orf14_1700012A16Rik, as the protein's activity is contingent on the proper signaling through mTORC1. Other inhibitors, like LY 294002, PF-04691502, and dual inhibitors such as PP242 and AZD8055, exert their effects by hindering both mTORC1 and mTORC2 or the PI3K-AKT-mTOR pathway, which is a precursor to mTOR activation.
Furthermore, compounds like WYE-125132, Torin 2 and OSI-027 which are also part of this inhibitor class, employ a strategy of ATP-competitive inhibition to obstruct both mTOR complexes. By doing so, they ensure that the mTOR pathway is sufficiently suppressed, leading to a concomitant diminishment in the activity of C1orf14_1700012A16Rik. The precision of these inhibitors lies in their ability to target the mTOR pathway at multiple points, thus ensuring a comprehensive inhibition. This direct interference with the mTOR pathway, which is central to the function of C1orf14_1700012A16Rik, underscores the specificity of these inhibitors and their role in reducing the protein's activity. They exemplify the focused approach of chemical inhibition where the blockade of upstream regulators or direct interaction with the signaling pathway leads to a profound and targeted reduction in protein function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is a specific inhibitor of the mTOR (mechanistic target of rapamycin) pathway. C1orf14_1700012A16Rik is known to be a part of cellular growth and metabolism regulated by mTOR signaling. By inhibiting mTOR, Rapamycin diminishes the downstream signaling cascade, leading to a reduction in the functional activity of C1orf14_1700012A16Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a potent inhibitor of the phosphoinositide 3-kinases (PI3K). Since PI3K signaling is upstream of mTOR and the PI3K-AKT-mTOR pathway is crucial for protein synthesis and cell survival, inhibition by LY 294002 would lead to a decrease in mTOR activity thereby reducing the functional activity of C1orf14_1700012A16Rik which is part of this signaling axis. | ||||||
WYE-125132 | 1144068-46-1 | sc-364651 sc-364651A | 10 mg 50 mg | $510.00 $1536.00 | ||
WYE-125132 is a highly selective inhibitor of mTOR. It reduces the activity of mTORC1 and mTORC2 complexes, which are central to the mTOR signaling pathway. This results in the decreased activity of C1orf14_1700012A16Rik due to its reliance on mTOR signaling for its functional activity. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus is an mTOR inhibitor similar to rapamycin. By binding to FKBP-12 and thereby inhibiting mTOR complex 1 (mTORC1), Everolimus diminishes the signaling required for cell growth and proliferation. This would result in decreased activity of C1orf14_1700012A16Rik, which is involved in these cellular processes. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $56.00 $169.00 | 8 | |
PP242 is an inhibitor of both mTORC1 and mTORC2 complexes. By inhibiting these complexes, PP242 disrupts the mTOR signaling pathway. This action results in diminished function of C1orf14_1700012A16Rik due to its dependence on mTOR pathway activity for its role in cellular processes. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
AZD8055 is a selective inhibitor of both mTORC1 and mTORC2. By targeting these complexes, AZD8055 impairs the mTOR signaling pathway, resulting in a reduced activity of proteins involved in this pathway, including C1orf14_1700012A16Rik. | ||||||
OSI-027 | 936890-98-1 | sc-364557 sc-364557A | 10 mg 50 mg | $428.00 $1163.00 | 1 | |
OSI-027 is a selective ATP-competitive inhibitor of mTORC1 and mTORC2. The inhibition of these complexes leads to a reduction in mTOR pathway signaling, which C1orf14_1700012A16Rik is reliant upon. Therefore, OSI-027 diminishes the functional activity of C1orf14_1700012A16Rik by impairing the pathway that regulates its activity. | ||||||